Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

被引:315
作者
Kosorok, MR
Zeng, L
West, SEH
Rock, MJ
Splaingard, ML
Laxova, A
Green, CG
Collins, J
Farrell, PM
机构
[1] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA
[2] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA
关键词
cystic fibrosis; Pseudomonas aeruginosa; infection; epidemiology;
D O I
10.1002/ppul.2009.abs
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
As part of the ongoing Wisconsin Cystic Fibrosis (CF) Neonatal Screening Project, we had the unique opportunity to study the longitudinal relationship between Pseudomonas aeruginosa (Fa) acquisition and infection and developing lung disease in children with CF. The primary objective was to determine whether acquisition of Pa was associated with a measurable change in the progression of lung disease. Two outcome measures were used to study 56 patients who were diagnosed through newborn screening: 1) Wisconsin additive chest radiograph score (WCXR), based on the average of scores from a pulmonologist and a radiologist, and 2) the highest forced expired volume in 1 sec (FEV1)/forced vital capacity (FVC) ratio. We used two measures of Fa acquisition: 1) time of first positive protocol-determined oropharyngeal (with cough) culture, and 2) the magnitude of antibody titer detected by ELISA assays, using as antigen a crude cell lysate, purified exotaxin A, or an elastase toxoid prepared from three Pa strains. Other predictor variables included age, pancreatic status, height-for age, and weight-for-age-percentiles. The best regression model for predicting changes in the WCXR included time to first positive culture and antibody titer for Pa elastase. Prior to Pa acquisition, WCXR worsened by 0.45 points/year (P > 0.26); after Pa acquisition, the rate of worsening increased significantly (P < 0.001) to 1.40 points/year. Each antibody titer level (log base 2) increased the score by 0.48 points (P < 0.001). The best regression model for predicting change in the FEV1/FVC included only time to first positive culture. Prior to Pa acquisition, the FEV1/FVC ratio declined by 1.291%/year; after Pa infection, the rate of decrease significantly accelerated to 1.81%/year (P = 0.001), Our data show that Pa acquisition is associated with declining pulmonary status in children with CF, and that this effect is probably gradual rather than precipitous. Because these patients were diagnosed and treated aggressively, our estimates of the effects of Pa acquisition may be conservative. We also conclude that the WCXR appears to be more sensitive than FEV1/FVC in detecting early changes in lung disease associated with CF. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:277 / 287
页数:11
相关论文
共 40 条
[1]   EARLY BACTERIOLOGICAL, IMMUNOLOGICAL, AND CLINICAL COURSES OF YOUNG INFANTS WITH CYSTIC-FIBROSIS IDENTIFIED BY NEONATAL SCREENING [J].
ABMAN, SH ;
OGLE, JW ;
HARBECK, RJ ;
BUTLERSIMON, N ;
HAMMOND, KB ;
ACCURSO, FJ .
JOURNAL OF PEDIATRICS, 1991, 119 (02) :211-217
[2]  
Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO
[3]  
2-K
[4]   THE VALUE OF SERUM IGG TITERS AGAINST PSEUDOMONAS-AERUGINOSA IN THE MANAGEMENT OF EARLY PSEUDOMONAL INFECTION IN CYSTIC-FIBROSIS [J].
BRETT, MM ;
SIMMONDS, EJ ;
GHONEIM, ATM ;
LITTLEWOOD, JM .
ARCHIVES OF DISEASE IN CHILDHOOD, 1992, 67 (09) :1086-1088
[5]   Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis [J].
Burns, JL ;
Gibson, RL ;
McNamara, S ;
Yim, D ;
Emerson, J ;
Rosenfeld, M ;
Hiatt, P ;
McCcoy, K ;
Castile, R ;
Smith, AL ;
Ramsey, BW .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (03) :444-452
[6]  
Di Sant'Agnese P A, 1976, N Engl J Med, V295, P481, DOI 10.1056/NEJM197608262950905
[7]  
Diggle P. J., 2002, ANAL LONGITUDINAL DA
[8]   Cystic fibrosis: gene therapy or preventive gene transfer? [J].
Drittanti, L ;
Masciovecchio, MV ;
Gabbarini, J ;
Vega, M .
GENE THERAPY, 1997, 4 (10) :1001-1003
[9]  
Farrell P. M., 1992, ADV PEDIATR, V39, P31
[10]   Nutritional benefits of neonatal screening for cystic fibrosis [J].
Farrell, PM ;
Kosorok, MR ;
Laxova, A ;
Shen, GH ;
Koscik, RE ;
Bruns, WT ;
Splaingard, M ;
Mischler, EH .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (14) :963-969